ClinicalTrials.gg
CompletedNCT00946699Updated Nov 13, 2014

A Study of the Safety and Tolerability of MEDI-551 in Scleroderma

A Phase 1 interventional study of MEDI-551 and Placebo in Scleroderma, sponsored by MedImmune LLC. Completed at 14 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-11-13.

Sponsored by MedImmune LLC (part of AstraZeneca) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 153 studies in Scleroderma, Diffuse with a site in United States — 29 open to participants now, 39 under way, 5 of them phase 3. Scleroderma, Diffuse · United States.

Enrollment
44th of 120
50 · median 29
Started
2010
with 5 others
Phase 1
23 of 153
6 open now
Registered
39th of 153
by date

Among the 153 studies in Scleroderma, Diffuse with a site in United States, this one is the 44th largest by enrollment of the 120 interventional ones that give a count, is one of 6 that started in 2010, is one of 23 in phase 1, and was the 39th registered.

Scleroderma, Diffuse

310 studies on the registry are indexed under Scleroderma, Diffuse; 76 are open to participants now.

Browse Scleroderma, Diffuse studies →

Open to participants now

29 of the 153 studies in Scleroderma, Diffuse with a site in United States are open now. Recruiting first, the newest first:

24 more — sign in →

All 29 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 55 Scleroderma, Diffuse studies recruiting now, 28 (51%) set no upper age limit and 20 (36%) stop at 75 or younger; 10 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 153 studies in Scleroderma, Diffuse with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the safety and tolerability of intravenously administered MEDI-551 over escalating single doses in adult subjects with Scleroderma

Read the detailed description

To evaluate the safety and tolerability of escalating single IV doses of MEDI-551 in adult subjects with scleroderma who have at least moderate skin thickening in an area suitable for repeat biopsy.

03

Conditions studied

  • Scleroderma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects
  • Age ≥ 18 years of age at the time of screening
  • Written and HIPAA authorization (applies to covered entities in the USA only) obtained from the subject/legal representative prior to performing any protocol-related procedures, including screening evaluations
  • Must fulfill the American Rheumatism Association (American College of Rheumatology) preliminary classification criteria for systemic sclerosis
  • Has at least moderate skin thickening (score of at least 2 by mRTSS) in at least one area suitable for repeat , such as on the arms, legs, or trunk
  • Females of , unless surgically sterile (ie, bilateral tubal ligation, bilateral oophorectomy, or complete hysterectomy), has sterile male partner, is at least 2 years post menopause, or practices abstinence, must use 2 effective methods of avoiding pregnancy (including oral, transdermal, or implanted , intrauterine device, female condom with spermicide, diaphragm with spermicide, cervical cap, or use of a condom with spermicide by the sexual partner), from screening, and must agree to continue using such precautions through the Early Discontinuation Visit/End of Study (Day 85, single-dose cohorts); cessation of birth control should not occur until 5 half-lives post-cessation of MEDI-551, 5 half-lives is estimated to be 75 days
  • Men, unless surgically sterile, must use 2 effective methods of birth control with a female partner and must agree to continue using such contraceptive precautions from Day 1 through the Early Discontinuation Visit/End of Study (Day 85, single-dose cohorts) and for 5 half-lives post-cessation of MEDI-551, 5 half-lives is estimated to be 75 days
  • Ability to complete the study period, including follow-up period through Day 85
  • Willingness to forego other forms of experimental treatment during the study (Day 1 through the Early Discontinuation Visit/End of Study - Day 85, single-dose cohorts)

Exclusion criteria

Exclusion Criteria:

  • History of allergic reactions to any component of the product
  • History of coagulation disorders that in the opinion of the investigator would contraindicate skin
  • Has a body weight ≥ 120 kg or \< 40 kg
  • Has B-cell count in peripheral blood \< 50% lower limit of normal (LLN) at screening
  • Forced vital capacity (FVC) \< 55% predicted, diffusing capacity for carbon monoxide (DLCO) \< 40% predicted, pulmonary hypertension requiring treatment with endothelin receptor antagonists or prostacyclin analogues
  • Scleroderma renal crisis within the last year, or medically significant malabsorption
  • Receipt of any B-cell-depleting biologic therapies at any time, such as rituximab
  • Receipt of leflunomide > 20 mg/day within 6 months prior to randomization into the study
  • Receipt of the following concomitant medications within 21 days prior to randomization into the study:

    • Prednisone > 30 mg/day or > 0.5 mg/kg
    • Cyclophosphamide
    • Systemic cyclosporine
    • Thalidomide
    • Hydroxychloroquine > 600 mg/day
    • Mycophenolate mofetil > 3 g/day
    • Methotrexate > 25 mg/week
    • Azathioprine > 3 mg/kg/day
    • Concomitant methotrexate and leflunomide
    • Any investigational drug therapy or non-B-cell-depleting biologic therapy (or within 5 half-lives of ingestion, whichever is longer)
  • Change in standing daily dosage of the following within 21 days before randomization into the study:

    • Antimalarials
    • Mycophenolate mofetil
    • Methotrexate
    • Leflunomide
    • Azathioprine
    • Systemic
  • At screening blood tests (within 21 days prior to randomization into the study), any of the following:

    • (AST) > 1.5 × (ULN)unless due to documented myositis
    • Alanine aminotransferase (ALT) > 1.5 × ULN unless due to documented myositis
    • Total > ULN, unless because of known Gilbert's disease - Total immunoglobin \<500 mg/dl
    • Creatinine > 2.5 mg/dL
    • Neutrophils \< 1,500/mm3
    • count \< 75,000/mm3
    • (Hgb) \< 8 g/dL
    • (HbA1c) > 8% at screening (diabetic subjects only)
    • Positive serum βHCG (pregnancy test)
  • Lactating woman
  • Herpes zoster infection within 3 months before randomization
  • A history of severe viral infection as judged by the investigator, including severe infections of either cytomegalovirus or the herpes family such as disseminated herpes, herpes encephalitis, ophthalmic herpes
  • At screening, positive tests for active hepatitis A, surface antigen (HbsAg), Hepatitis B core antibody (HbcAb) or serology, or -1 or -2 (HIV-1/2). False positive tests are not included.
  • Deep space/tissue infection (eg, fasciitis, abscess, osteomyelitis, or infected joint replacements) within 1 year before randomization into the study
  • Any opportunistic infection or serious infection (in the opinion of the investigator) within 6 months prior to screening
  • Any of the following within 21 days before randomization into the study:

    • active infection, including ongoing, chronic infection
    • Any infection requiring hospitalization or treatment with IV anti-infectives
  • Completion of a course of oral anti-infectives within 14 days before randomization into the study
  • Any acute illness or evidence of clinically significant active infection, such as fever ≥ 38.0 degrees C (≥ 100.5 degrees F) at screening or at Day 1
  • Evidence of active tuberculosis (TB), either treated or untreated, or latent TB without completion of an appropriate course of treatment or appropriate ongoing prophylactic treatment. Evaluation and treatment will be according to the local standard of care and may consist of history and physical examinations, and/or chest X ray, and/or TB test (eg. purified protein derivative) testing, with the standard of care as determined by local guidelines
  • History of primary immunodeficiency or underlying condition that predisposes the subject to infection (eg, splenectomy)
  • Receipt of any live or attenuated vaccine within 21 days before randomization into the study or anticipated to be given within 5 half-lives of the last dose of investigational product administration, half-life is estimated to be approximately 15 days. Therefore, receipt of should be avoided for 75 days post dose of investigational product
  • Medically indicated adult immunizations that are not current (eg, pneumococcal vaccine)
  • Current evidence of alcohol, drug or chemical abuse, or a recent history of such abuse \< 1 year prior to randomization into the study
  • History of cancer except basal cell carcinoma treated with apparent success with curative therapy ≥ 1 year prior to randomization into the study
  • Major surgery within 8 weeks before randomization into the study or elective surgery planned from screening through the Early Discontinuation Visit/End of Study (Day 85, single-dose cohorts)
  • History of any disease, evidence of any current disease (other than scleroderma), any finding upon physical examination, chest x-ray, or any laboratory abnormality that, in the opinion of the investigator or medical monitor, may compromise the safety of the subject in the study or confound the analysis of the study
  • Any institutionalized individual
  • Employees of the clinical study site or any other individuals involved with the conduct of the study, or immediate family members of such individuals
  • Concurrent enrollment in another clinical study with the exception of observational or interventional studies that do not involve therapeutic strategies or invasive diagnostic tests
  • Concurrent enrollment in another clinical study with an investigational product administered within 4 weeks prior to Day 1 or within 5 half-lives of the investigational product, whichever is longer
  • Known sensitivity to acetaminophen/paracetamol, diphenhydramine, and methylprednisolone or equivalent glucocorticoid
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Double (Participant, Investigator)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    1

    MEDI-551

    Biological: MEDI-551

  • Experimental
    2

    MEDI-551

    Biological: Placebo

  • Experimental
    3

    MEWDI-551

    Biological: MEDI-551

  • Experimental
    4

    MEDI-551

    Biological: MEDI-551

  • Experimental
    5

    MEDI-551

    Biological: MEDI-551

  • Placebo comparator
    6

    Placebo

    Other: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. The safety and tolerability of MEDI-551 will be assessed primarily by summarizing treatment-emergent AEs and SAEs.

    Time frame: Day 85

Secondary outcomes

  1. The secondary endpoints of the study are to assess the PK, IM, and PD of single IV doses of MEDI-551 in adult subjects with scleroderma. Pharmacodynamics will be assessed by numbers of B cells in blood and skin.

    Time frame: Day 85

07

Study locations

14 sites
  • Research Site
    Loma Linda, California, United States
  • Research Site
    Redwood City, California, United States
  • Research Site
    Farmington, Connecticut, United States
  • Research Site
    Shreveport, Louisiana, United States
  • Research Site
    Worcester, Massachusetts, United States
  • Research Site
    Ann Arbor, Michigan, United States
  • Research Site
    New Brunswick, New Jersey, United States
  • Research Site
    Great Neck, New York, United States
  • Research Site
    Durham, North Carolina, United States
  • Research Site
    Cleveland, Ohio, United States
  • Research Site
    Duncansville, Pennsylvania, United States
  • Research Site
    Dallas, Texas, United States
  • Research Site
    Winnipeg, Manitoba, Canada
  • Research Site
    London, United Kingdom
08

References and documents

Publications

  • Schiopu E, Chatterjee S, Hsu V, Flor A, Cimbora D, Patra K, Yao W, Li J, Streicher K, McKeever K, White B, Katz E, Drappa J, Sweeny S, Herbst R. Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study. Arthritis Res Ther. 2016 Jun 7;18(1):131. doi: 10.1186/s13075-016-1021-2. PubMed 27267753 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2010, a primary completion of Mar 2012 and a completion of Mar 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2009
First posted
Jul 27, 2009
Start
Mar 2010
Primary completionActual
Mar 2012
CompletionActual
Mar 2014
Last update
Nov 13, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 13, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00946699
Lead sponsor
MedImmune LLC
Responsible party
Sponsor
First posted
Jul 27, 2009
Start date
Mar 2010
Primary completion
Mar 2012
Completion
Mar 2014
Last update
Nov 13, 2014

Study contacts

Medical Monitor
study director · MedImmune LLC

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Inebilizumab

Start the discussion